Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Consensus Recommendation of “Hold” from Analysts

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has been assigned an average recommendation of “Hold” from the eight analysts that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $6.75.

Several brokerages recently weighed in on INO. Weiss Ratings reissued a “sell (d-)” rating on shares of Inovio Pharmaceuticals in a research note on Monday, December 29th. Wall Street Zen raised Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday. Oppenheimer reaffirmed an “outperform” rating on shares of Inovio Pharmaceuticals in a report on Friday. Finally, HC Wainwright reiterated a “neutral” rating on shares of Inovio Pharmaceuticals in a research report on Tuesday, December 30th.

Institutional Trading of Inovio Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in INO. Boxer Capital Management LLC acquired a new stake in Inovio Pharmaceuticals during the 3rd quarter valued at approximately $5,382,000. Raymond James Financial Inc. lifted its position in shares of Inovio Pharmaceuticals by 4,396.0% in the 3rd quarter. Raymond James Financial Inc. now owns 16,680 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 16,309 shares during the period. Caitong International Asset Management Co. Ltd boosted its stake in shares of Inovio Pharmaceuticals by 752.9% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 20,572 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 18,160 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Inovio Pharmaceuticals by 39.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 5,894 shares during the last quarter. Finally, Focus Partners Wealth acquired a new stake in shares of Inovio Pharmaceuticals during the third quarter worth $33,000. 26.79% of the stock is currently owned by institutional investors.

Inovio Pharmaceuticals Price Performance

NASDAQ:INO opened at $1.66 on Monday. Inovio Pharmaceuticals has a one year low of $1.30 and a one year high of $2.98. The company has a market cap of $114.69 million, a PE ratio of -0.99 and a beta of 1.70. The firm’s 50 day simple moving average is $1.65 and its 200 day simple moving average is $2.05.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings results on Thursday, March 12th. The biopharmaceutical company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.68. The business had revenue of ($0.07) million during the quarter, compared to analyst estimates of $0.33 million. Equities research analysts expect that Inovio Pharmaceuticals will post -4.23 EPS for the current year.

Inovio Pharmaceuticals News Roundup

Here are the key news stories impacting Inovio Pharmaceuticals this week:

• Positive Sentiment: BLA accepted under the FDA’s Accelerated Approval Program for INO‑3107 (potential RRP treatment); PDUFA date set for Oct. 30, 2026 — a clear regulatory milestone that could materially de‑risk and create commercial value if approved. INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Q4 2025 results showed a surprising EPS beat (reported $0.31 vs. consensus ~($0.37)), which reduces short‑term earnings uncertainty. The company also highlighted published clinical/immunology data and advancing next‑generation DNA medicine technologies (DMAbs, DPROT). INOVIO Reports Fourth Quarter and Full Year 2025
• Neutral Sentiment: Management discussed strategic moves and regulatory planning on the Q4 earnings call; investors should listen for commercialization plans, cash‑burn guidance, and timelines for INO‑3107 ahead of the October PDUFA. Earnings Call Highlights
• Negative Sentiment: Multiple law firms have filed or are soliciting lead‑plaintiff actions alleging securities fraud for the Oct. 10, 2023–Dec. 26, 2025 class period; several reminders cite an April 7, 2026 deadline — this legal overhang increases litigation risk, potential settlement exposure, and headline volatility. Representative notices: Glancy Prongay Wolke & Rotter and Schall Law Firm. Deadline Alert: Glancy Prongay Wolke & Rotter Schall Law Firm Notice
• Negative Sentiment: Revenue metrics missed expectations (press coverage shows revenue below consensus), and sell‑side models still forecast a negative FY EPS (analyst consensus cited ~‑4.23), implying continued cash‑flow and financing risk that could dilute shareholders. MarketBeat INO snapshot
• Negative Sentiment: Technical/market context: the 50‑day moving average sits below the 200‑day, and volume is below average — factors that can amplify downside during negative headlines. Interactive Chart

About Inovio Pharmaceuticals

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.